Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue.
The phytocannabinoid cannabidiol (CBD) possesses no psychotropic activity amid potentially beneficial therapeutic applications. We here characterized interactions between CBD (1 microM) and the endocannabinoid system in cultured rat hippocampal cells. The CBD-induced Ca2+ rise observed in neurons and glia was markedly reduced in the presence of the endogenous cannabinoid anandamide in neurons, with no alteration seen in glia. Neuronal CBD responses were even more reduced in the presence of the more abundant endocannabinoid 2-arachidonyl glycerol, this action was maintained in the presence of the CB1 receptor antagonist AM281 (100 nM). Neuronal CBD responses were also reduced by pre-exposure to glutamate, expected to increase endocannabinoid levels by increasing in [Ca2+]i. Application of AM281 at 1 microM elevated CBD-induced Ca2+ responses in both cell types, further confirming our finding that endocannabinoid-mediated signalling is negatively coupled to the action of CBD. However, upregulation of endogenous levels of endocannabinoids via inhibition of endocannabinoid hydrolysis (with URB597 and MAFP) could not be achieved under resting conditions. Because delta9-tetrahydrocannabinol did not mimic the endocannabinoid actions, and pertussis toxin treatment had no effect on CBD responses, we propose that the effects of AM281 were mediated via a constitutively active signalling pathway independent of CB1 signalling. Instead, signalling via G(q/11) and phospholipase C appears to be negatively coupled to CBD-induced Ca2+ responses, as the inhibitor U73122 enhanced CBD responses. Our data highlight the interaction between exogenous and endogenous cannabinoid signalling, and provide evidence for the presence of an additional pharmacological target, sensitive to endocannabinoids and to AM281.
Ryan
Duncan
D
School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD Scotland, UK.
Drysdale
Alison J
AJ
Pertwee
Roger G
RG
Platt
Bettina
B
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D001549:Benzamides / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002185:Cannabidiol / Q000378:metabolism*; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D002219:Carbamates / Q000378:metabolism; D002478:Cells, Cultured; D013759:Dronabinol / Q000378:metabolism; D063388:Endocannabinoids; D004963:Estrenes / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D005989:Glycerides / Q000378:metabolism; D006624:Hippocampus / Q000166:cytology / Q000502:physiology*; D006801:Humans; D009025:Morpholines / Q000378:metabolism; D037342:Pertussis Toxin / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000378:metabolism; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D011720:Pyrazoles / Q000378:metabolism; D011760:Pyrrolidinones / Q000378:metabolism; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*
D001095:Arachidonic Acids; D001549:Benzamides; D063385:Cannabinoid Receptor Modulators; D002219:Carbamates; D063388:Endocannabinoids; D004963:Estrenes; D005989:Glycerides; D009025:Morpholines; D010726:Phosphodiesterase Inhibitors; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D011760:Pyrrolidinones; D043884:Receptor, Cannabinoid, CB1; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D002185:Cannabidiol; D018698:Glutamic Acid; D013759:Dronabinol; C094503:glyceryl 2-arachidonate; D037342:Pertussis Toxin; C109925:AM 281; D002118:Calcium; C078814:anandamide